ReproCELL Past Earnings Performance
Past criteria checks 0/6
ReproCELL has been growing earnings at an average annual rate of 35.5%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 19.6% per year.
Key information
35.5%
Earnings growth rate
38.8%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 19.6% |
| Return on equity | -2.2% |
| Net Margin | -7.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How ReproCELL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,599 | -195 | 1,177 | 453 |
| 30 Jun 24 | 2,489 | -178 | 1,187 | 418 |
| 31 Mar 24 | 2,426 | -31 | 1,131 | 384 |
| 31 Dec 23 | 2,506 | -218 | 1,088 | 429 |
| 30 Sep 23 | 2,524 | -313 | 1,057 | 459 |
| 30 Jun 23 | 2,843 | -275 | 1,010 | 481 |
| 31 Mar 23 | 2,953 | -305 | 984 | 501 |
| 31 Dec 22 | 2,969 | -263 | 936 | 468 |
| 30 Sep 22 | 2,821 | -306 | 927 | 466 |
| 30 Jun 22 | 2,518 | -411 | 893 | 466 |
| 31 Mar 22 | 2,234 | -575 | 898 | 535 |
| 31 Dec 21 | 1,825 | -505 | 898 | 571 |
| 30 Sep 21 | 1,661 | -648 | 875 | 642 |
| 30 Jun 21 | 1,500 | -726 | 884 | 713 |
| 31 Mar 21 | 1,286 | -812 | 843 | 662 |
| 31 Dec 20 | 1,257 | -1,011 | 883 | 626 |
| 30 Sep 20 | 1,249 | -945 | 859 | 558 |
| 30 Jun 20 | 1,111 | -995 | 859 | 482 |
| 31 Mar 20 | 1,199 | -1,016 | 889 | 454 |
| 31 Dec 19 | 1,173 | -834 | 886 | 388 |
| 30 Sep 19 | 1,114 | -809 | 943 | 317 |
| 30 Jun 19 | 1,090 | -750 | 964 | 282 |
| 31 Mar 19 | 1,088 | -601 | 971 | 273 |
| 31 Dec 18 | 1,046 | -1,950 | 805 | 277 |
| 30 Sep 18 | 1,018 | -1,965 | 846 | 264 |
| 30 Jun 18 | 969 | -2,052 | 908 | 233 |
| 31 Mar 18 | 926 | -2,172 | 982 | 191 |
| 31 Dec 17 | 1,083 | -1,019 | 1,122 | 203 |
| 30 Sep 17 | 1,187 | -759 | 1,071 | 237 |
| 30 Jun 17 | 1,202 | -765 | 1,031 | 256 |
| 31 Mar 17 | 1,257 | -911 | 1,011 | 276 |
| 31 Dec 16 | 1,136 | -1,838 | 882 | 277 |
| 30 Sep 16 | 1,043 | -2,150 | 958 | 274 |
| 30 Jun 16 | 1,069 | -2,199 | 984 | 282 |
| 31 Mar 16 | 1,066 | -1,961 | 979 | 289 |
| 31 Dec 15 | 1,023 | -791 | 1,218 | 337 |
| 30 Sep 15 | 917 | -720 | 1,111 | 340 |
| 30 Jun 15 | 743 | -518 | 947 | 316 |
| 31 Mar 15 | 567 | -451 | 736 | 280 |
| 31 Dec 14 | 473 | -359 | 487 | 186 |
| 30 Sep 14 | 463 | -187 | 345 | 147 |
| 30 Jun 14 | 462 | -140 | 268 | 133 |
| 31 Mar 14 | 460 | -133 | 229 | 120 |
Quality Earnings: 4978 is currently unprofitable.
Growing Profit Margin: 4978 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4978 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.5% per year.
Accelerating Growth: Unable to compare 4978's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4978 has a negative Return on Equity (-2.23%), as it is currently unprofitable.